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Abstract:  
An American study has concluded that people with cancer who receive 
complementary medicine (CM) have a twofold greater risk of death compared with 
patients who had no CM. The Yale University study is presented as an assessment 
of ‘complementary’ rather than ‘alternative’ therapies, but this critical analysis 
suggests it fails to differentiate between the two approaches to the use of 
unconventional interventions. It also fails to address the complex factors involved in 
its authors’ question: ‘What patient characteristics are associated with the use of CM 
for cancer and what is the association of CM with treatment adherence and 
survival?’.  
By considering the US study in the context of conditions and developments in the 
UK, this article offers insights into ways appropriately trained and regulated 
complementary therapists could play a useful role in new models of care. It also 
identifies areas for further investigation.  
Background: 
Doctors at Yale School of Medicine (Johnson et al 2018a, 2018b) have conducted a 
retrospective observational study drawing on data from the US National Cancer 
Database on more than 1 million patients who had been diagnosed with non-
metastatic breast, prostate, lung and colorectal cancer. They first identified people 
who had received one or more conventional cancer treatments (CCTs), such as 
surgery, chemotherapy, radiotherapy and hormone therapy, then searched this 
group for people whose notes carried the code ‘Other-unproven: cancer treatments 
administered by nonmedical personnel’. Their data analysis, which concerned overall 
survival rates and adherence to treatment, showed that this subgroup had a higher 
refusal rate of additional conventional treatment compared with people who did not 
have the other-unproven code on their records. Johnson et al’s (2018b) study 
concludes that ‘patients who received CM were more likely to refuse additional CCT 
and had a higher risk of death’.  This article examines: the assumptions the authors 
made; the conclusions they drew; and the implications for research into, and use of, 
complementary therapies in supportive and palliative care in the UK.  
Alternative v complementary  
The researchers had previously conducted a similar study into survivorship among 
people with nonmetastatic cancers drawing on the same database (Johnson et al 
2018a). In this study, they examined the data of patients who had the other-
unproven code in their notes but had not undergone CCT. These cases were defined 
as examples of ‘alternative medicine’. A main purpose of Johnson et al’s (2018b) 
study was to differentiate between alternative medicine and complementary 
medicine (CM), whereby patients who had received CM were defined as those who 
had also received CCT but had the other-unproven code in their records.  
The British Medical Association (BMA) defines complementary therapies as non-
conventional treatments that ‘work alongside or in conjunction with orthodox medical 
treatment’ and alternative therapies as those ‘given in place of orthodox medical 
treatment’ (BMA 1993). So, if a patient refuses or delays a CCT in favour of a non-
conventional therapy, the change in intent means the therapy is regarded as 
‘alternative’ rather than ‘complementary’. So, according to the BMA’s definitions, a 
patient who has a reiki session during chemotherapy is receiving a nonmedical 
intervention that is complementary to the mainstream treatment. Even if the 
chemotherapy unit offers reiki as part of a deliberate strategy to encourage patients 
to complete their courses of chemotherapy, the treatment is still integrated and 
therefore complementary. But if the reiki treatment is given instead of interventions 
recommended by the oncologist, it should be regarded as alternative.  
The researchers observe that their work ‘demonstrates that patients who use 
alternative medicine and CM are often behaving similarly in refusing conventional 
treatment.’ But at the moment where mainstream cancer treatment is refused in 
favour of a non-conventional therapy, that therapy is no longer complementary. The 
Yale researchers acknowledge the existence of this transitional moment: ‘It is 
possible that clinicians were more likely to document the use of CM when patients 
were using noteworthy therapies that may have resulted in refusal of CCT.’ In effect, 
the clinicians were logging the moment when the shift of patients from CM to 
alternative medicine took place. However, the researchers fail to grasp the 
significance of this moment, as is evident in their claim that users of complementary 
and alternative approaches ‘are often behaving similarly in refusing conventional 
treatment’. This contradiction of terms is embedded in the headline of the Yale 
Cancer Centre’s (2018) press statement: ‘Replacing conventional medicine for 
complementary therapy can decrease survival’ – a ‘replacement’ is an alternative, 
not an adjunct.  
The Yale studies indicate that alternative medicine is culpable for poorer outcomes, 
but they cannot prove the guilt of complementary therapies. In the press release, co-
author Cary Gross calls for further research, saying: ‘The sources of misinformation 
need to be better understood.’ This is necessary, but the study is itself a source of 
misinformation.  
Cultural differences  
People with cancer in the UK routinely access complementary therapies to help them 
cope with side-effects and stress, enhancing quality of life and improving treatment 
compliance (Baldwin and Woodhouse 2011). These are not ‘cancer treatments’, 
however. In the UK, only doctors, nurses and pharmacists can promote or prescribe 
cancer treatment, and the administration of ‘unproven cancer treatments by 
nonmedical personnel’ is against the law. If a therapist claims their intervention can 
cure cancer, they are committing an offence under the Cancer Act 1939, Section 4.  
In the US, the emphasis is placed on freedom of choice, and this includes the 
freedom to access unconventional therapies for the treatment of cancer. Regulation 
varies from state to state (World Health Organization 2001). Consequently, 
alternative therapies to treat cancer are so prevalent their use warrants a code in 
patients’ medical notes. Moreover, US patients over the age of 21 who use Medicare 
and have a condition that could cause death within six months are faced with a 
choice: pursue a cure or access palliation. Their Medicare insurance does not cover 
both (Centers for Medicare and Medicaid Services 2018).  
The researchers observed that logs of other-unproven treatment codes ‘differed 
significantly by facility’, which could be because some treatment facilities have lower 
thresholds for deciding which therapies are significant enough to record or because 
clusters of people using the facilities were particularly drawn to other-unproven 
treatments. Patients identified in the study as ‘CM users’ tended to be younger, well-
off, well-educated and otherwise healthy women from Arizona, California, Hawaii, 
Oregon and Washington, where there are high concentrations of complementary and 
alternative medicine (CAM) schools and state legislation favouring CAM (Barnes et 
al 2004). Whether these women had been targeted by commercial enterprises 
exploiting lax state laws warrants further investigation. The researchers rightly call 
for action to ensure that patients ‘aren’t being sold a false bill of goods’ and warn 
against the marketing of alternative therapies as effective cancer treatments. 
Misinformation moves across international boundaries, often fuelled by social media 
networks, and many ‘healthy living’ marketing scams prioritise selling product over its 
responsible use.  
Study design  
The researchers claim that their study aims to ‘investigate factors associated with the 
selection of CM’, but they did not gather data for that purpose. Theirs is a secondary 
analysis of a database of medical records.  
‘Curable’ cancers  
Their claim that the patients in the study have curable cancer is based on their 
exclusion of patients with metastatic disease at diagnosis, stage IV disease in the 
sample years, those who chose ‘upfront treatment with palliative intent’ and those 
with ‘unknown’ treatment status. The researchers say they were unaware of many 
aspects of the patients’ cancer experience that could influence survival, including the 
prognoses of specific cancers, details about stopped or dose-reduced treatments, 
and the burden of the disease and its treatment. There is also no record of the 
patients’ treatments for health problems other than cancer. All these factors may 
have had a significant influence on individual decisions to discontinue, delay or avoid 
conventional treatment.  
The continuation of complementary therapies to support a person who has decided 
to discontinue curative treatment cannot be compared with the use of non-
conventional therapies in the treatment of the cancer itself. The Yale study highlights 
the dangers of failing to adhere to conventional treatment plans. Patients must have 
a full grasp of these dangers to make informed decisions about their treatment. But 
conventional treatments can be risky, challenging and traumatic – as medical 
professionals are duty-bound to explain. Each patient must constantly weigh risk 
against benefit on the basis of full and objective information, and make their own 
decisions along the full course of their journeys. But this process is not addressed by 
the study.  
Therapies  
The researchers draw their conclusions despite an ‘absence of information regarding 
the type and total number of CM modalities used’. They claim that ‘CM and 
alternative medicine likely represent entities along a continuum’, but as has already 
been established, it is the application of a therapy, not the therapy itself, that defines 
whether an intervention is complementary or alternative. Rather than using the idea 
of a continuum, Hawks and Moyad (2003) refer to guidance from the US National 
Center for Complementary and Alternative Medicine to suggest five categories of 
other-unproven interventions: mind-body, such as meditation; biologically-based, 
such as herbalism; physical, such as massage; energy-based, such as reiki; and 
alternative medical systems, such as homeopathy. Each therapy has, or lacks, its 
own evidence base, as well as indications, contraindications, risks and benefits. 
Some, such as those involving ingestion of unverifiable substances, are inherently 
alternative and cannot be adapted to complement conventional care. Others, such 
as massage and cognitive behavioural therapy, have an evidence base that 
compares favourably with the benchmarks of mainstream medicine.  
Each interaction between therapist and patient multiplies the complexity of the issue 
under scrutiny. The nature of the therapeutic relationship (Budd and Ursula 1994, 
Fox 2008); the quality of training and regulation, and its influence on the therapist 
(Wilkinson and Gale 2015); the timeline of each patient’s journey; and the 
juxtaposition of conventional and unconventional therapies are all important factors 
in the evaluation of the safety, or otherwise, of each therapy when it is applied as 
complementary or alternative medicine. The full picture can only be ascertained by 
applying a range of research methods to these crucial details.  
Biomedical v biopsychosocial  
The study is grounded in the biomedical model of care, which assumes the main 
objective of treatment is survival. But, for some people already coping with complex, 
chronic conditions, their rejection of further aggressive cancer treatment is a positive 
choice: quality of life over quantity of life. Developments in cancer nursing follow the 
biopsychosocial model of care, which offers a realistic framework for ways of living 
with and beyond cancer. Unconventional therapies can appear attractive to some 
patients, and the people they meet can have a profound influence on their choices 
and opinions. The researchers point to evidence suggesting that a less hopeful 
cancer prognosis is associated with use of non-conventional therapies. They 
consider the possibility that late diagnosis occurs when people believe that 
unconventional treatments make mainstream scanning and diagnostic procedures 
redundant. If this is the case, and the people concerned are undergoing non-
conventional therapies to avoid mainstream health interventions, their therapies can 
be described as alternative rather than complementary.  
The researchers conclude: ‘For patients with curable cancers who are inclined to 
pursue complementary treatment methods, timely adherence to all recommended 
conventional therapies should be strongly advised.’ Similar advice appears in the 
codes of conduct observed by accredited complementary therapists on the UK’s 
voluntary registers. Examples of good practice, where complementary therapists 
work as part of hospice multidisciplinary teams, are extensive, but there are many 
reasons why people with life-limiting conditions do not access such services and 
seek, either by choice or necessity, therapies from non-hospice-based providers. A 
deeper understanding of the complex interplay of these factors requires a 
complementary blend of quantitative and qualitative analysis (Dew 2012). The Yale 
studies are a starting point for this analysis in that they make clear the need for 
further research into what happens when people with cancer engage in non-
conventional therapies.  
The Yale researchers imply that complementary therapy is a kind of ‘gateway drug’ 
that prompts desire for more extreme non-conventional interventions and a rejection 
of conventional care. Integrative medicine has been described as ‘a way of 
smuggling alternative practices into rational medicine by way of lowered standards of 
critical thinking’ (McLachlan 2010). This claim also requires further investigation.  
Implications for practice  
In the UK, complementary therapists have been collaborating with mainstream 
health providers for over a decade to improve treatment compliance and quality of 
life for people with cancer. By applying their experience of cancer care to other 
patient groups, they have developed services tailored to the needs of a wide range 
of people, including those with dementia and other neurodegenerative disorders. 
Their efforts address problems for which mainstream medicine has few answers, 
thereby relieving pressure on hard-pressed health and social care services and 
supporting self-care, a key theme of NHS Sustainability and Transformation Plans 
(King’s Fund 2017).  
With the correct continuing professional development and support, complementary 
therapists could be ideally placed to inform and educate people accessing their 
services. In this context, the NHS Institute for Innovation and Improvement (2007) 
document Thinking Differently states: ‘Workforce planning should begin with the 
needs of the patient before looking at the skills and competencies required to meet 
these needs.’  
A framework for excellence is provided in National Guidelines for the Use of 
Complementary Therapies in Supportive and Palliative Care (Tavares 2003), and the 
Professional Standards Authority for Health and Care (PSA) accredits voluntary 
registers of complementary therapists who commit to standards and procedures. 
Bodies accredited by the PSA include the Complementary and Natural Healthcare 
Council (2018) and Federation of Holistic Therapists (2018). Their codes of conduct 
ban members from claiming to diagnose, treat, heal or cure medical conditions, or 
from advising a client to stop medication or treatment that has been prescribed or 
recommended by a statutorily regulated healthcare professional. They instruct 
therapists to direct their clients to their health professionals to discuss treatment 
decisions and to keep their clinical team informed of their use of complementary 
therapies. Therapists are obliged to make sure they do not give treatments a client’s 
health professional has advised against.  
The PSA and Royal Society for Public Health (2017) recognise the potential of 
accredited complementary therapists and have outlined a framework to support them 
in a public health role. Complementary therapists often have regular and relatively 
long sessions of contact with clients. The report identifies the potential within those 
sessions for the therapists to support their clients to make positive behaviour 
changes. The Health Education England (HEE 2018) initiative Making Every Contact 
Count offers training packages to maximise the potential of day-to-day interactions 
such as the provision of complementary therapy. Meanwhile, Public Health England 
(2017) is re-evaluating education, training and development within the health and 
social care support workforce. All these initiatives have potential to facilitate the 
appropriate involvement of complementary therapists in the wider health workforce.  
The RCNi Cancer Nursing Practice conference in Birmingham in May 2018, entitled 
Living With And Beyond, discussed new frameworks of care which could have the 
potential to utilise appropriately trained and regulated complementary therapists. 
Nurse specialist Sarah Orr and nurse consultant Natalie Doyle discussed the 
practicalities of delivering ‘individualised plans of care underpinned by self-
management with support from the right person, at the right place, at the right time’, 
as set out by Macmillan Cancer Support (2013). It may well be that hospice and 
hospital staff can identify complementary therapists who are already working 
alongside them who have the potential to play a supporting role in the Recovery 
Package outlined in the 2013 Macmillan report. If complementary therapists are 
experienced, well-prepared and supported, they can encourage patients to 
persevere with a structured, nurse-led self-management programme.  
Macmillan Cancer Support’s chief of nursing and allied health professionals Karen 
Roberts is in charge of monitoring skill mix and identifying new roles in cancer care 
as the ‘treatable, but not curable’ cancer category expands, increasing the pressure 
on resources. In the document Cancer Workforce in England (Macmillan Cancer 
Support 2018), she describes the key role of the ‘nonmedical adult cancer 
workforce’, and identifies bands 3 and 4 cancer support workers for development.  
A workshop on stratified follow-up care at the May 2018 RCNi Cancer Nursing 
Practice Conference, led by advanced care practitioner Claire Marsh and public 
health specialist Hazel Brodie, featured specific support tasks at band 4 that would 
lend themselves to the talents and accessibility of competent complementary 
therapists with the appropriate training, regulation, and mentoring. With the 
appropriate competencies and training, and nurse specialists as mentors, 
complementary therapists could be part of this system of support.  
There is an established demand for complementary and alternative medicine in 
cancer care that is unlikely to abate as survivorship increases, and care pathways 
become more complex and patient-led. The engagement, training and regulation of 
complementary therapists could make a significant contribution to new models of 
care. Decision-makers should look at the Yale research with a critical eye and 
augment quantitative analysis with a deeper investigation into the qualitative aspects 
of complementary therapies in palliative care. Failure to do so could halt the 
development of integrated therapies that relieve some of the caring burden from 
overstretched NHS services, and put pressure on charities that attract funding as a 
result of their responsible and measured provision of complementary therapies.  
Conclusion  
The researchers’ attempt to make the important distinction between alternative 
medicine and CM is welcome and timely, but fails to differentiate between the two 
appropriately. Information about individual patients in the study is insufficient to draw 
conclusions about their use, or the consequences of use, of non-conventional 
therapies because it was not collected with the purpose of the study in mind.  
More mixed-methods research is required, therefore, to explore the patient 
characteristics associated with the use of CM for cancer, and the association of CM 
with treatment adherence and survival.  
When interpreting the study’s findings, caution is also required because of 
differences in culture between US and UK cancer care, and CAM use. 
Developments in patient-centred care in the UK have created a place for well-
educated and regulated complementary therapists, but this could be jeopardised 
were the researchers’ conclusions to be taken at face value. Research is required to 
identify the education and regulation needed to integrate existing and future 
complementary therapists into new models of care. 
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